Table S3.
Combinations of COPD therapy during outcome year in each study cohort
| Inhaler therapy | n (%)
|
|
|---|---|---|
| Similar-devices cohort (n=8,225) | Mixed-devices cohort (n=8,225) | |
| LABA ± SAMA ± SABA | 604 (7.3) | 336 (4.1) |
| LAMA ± SAMA ± SABA | 471 (5.7) | 1,136 (13.8) |
| LABA + LAMA ± SAMA ± SABA | 51 (0.6) | 250 (3.0) |
| ICS ± SAMA ± SABA | 2,464 (30.0) | 653 (7.9) |
| ICS + LABA ± SAMA ± SABA | 3,680 (44.7) | 2,859 (34.8) |
| ICS + LAMA ± SAMA ± SABA | 90 (1.1) | 498 (6.1) |
| ICS + LABA + LAMA ± SAMA ± SABA | 780 (9.5) | 2,358 (28.7) |
| LABA + LTRA ± SAMA ± SABA | 0 (0.0) | 2 (0.0) |
| LAMA + LTRA ± SAMA ± SABA | 4 (0.1) | 3 (0.0) |
| ICS + LTRA ± SAMA ± SABA | 12 (0.2) | 3 (0.0) |
| ICS + LAMA + LTRA ± SAMA ± SABA | 4 (0.1) | 3 (0.0) |
| ICS + LABA + LAMA + LTRA ± SAMA ± SABA | 11 (0.1) | 48 (0.6) |
| ICS + LABA + LTRA ± SAMA +/i SABA | 53 (0.6) | 76 (0.9) |
| Others | 1 (0.0) | 0 (0.0) |
Abbreviations: SAMA, short-acting muscarinic agonist; SABA, short-acting beta agonist; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid; LTRA, leukotriene receptor antagonist.